Artificial intelligence (AI) and real-world NHS data will be used to improve medicines safety and speed up access to new treatments in three new UK Government-funded projects led by the Medicines and Healthcare products Regulatory Agency (MHRA).
One study, supported by £859,650 from the Government’s AI Capability Fund, will use AI to predict adverse effects arising from drug combinations before they reach patients.
The project, run by the MHRA alongside PhaSER Biomedical and the University of St Andrews, will analyse anonymised NHS data to identify patterns in how medicines interact, initially focusing on cardiovascular drugs.
The findings will then be validated in the lab using human-based models that replicate how medicines are metabolised.
The aim of the project is to create a tool that enables healthcare professionals to assess interactions and tailor prescriptions more safely and effectively.
According to the MHRA, the approach could help reduce medicine-related hospital admissions, which account for around one in six in England and cost the NHS more than £2bn annually.
‘Safer, smarter and more inclusive’
Two further MHRA initiatives will also receive funding through the Regulators’ Pioneer Fund. The £1m AI for Regulatory Insight, Safety and Efficiency (ARISE) programme will test how AI can support experts in scientific advice, clinical trial assessment and licensing decisions.
A separate £259,250 project will explore the use of synthetic patient data to strengthen trial evidence, particularly in rare and under-represented conditions.
Lawrence Tallon, MHRA chief executive, said the new programmes would make regulation ‘safer, smarter and more inclusive’, adding that the agency was committed to using real-world health data and advanced technologies to protect patients and support faster access to effective medicines.
Julian Beach, interim executive director for healthcare quality and access at the MHRA, said the work would show how AI and advanced modelling ‘can be built into drug development to design smarter, more efficient clinical trials’.
The announcement of the projects follows an NHS trial that found using AI to support administrative work could save an average of 43 minutes per day per staff member, which equates to five weeks annually.
Earlier this year, the International Pharmaceutical Federation published a position statement outlining the potential for AI to boost efficiency, optimise medication safety and improve personalised care in pharmacy.
And sessions at the ESCMID Global congress explored how AI is supporting the management of infectious diseases, as well as the associated risks and future directions.
A version of this article was originally published by our sister publication The Pharmacist.
